A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)

doi:10.1371/journal.pone.0242763

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24758

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24758

题名:	A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)
作者:	Chen, CP;Lin, YC;Chen, TC;Tseng, TY;Wong, HL;Kuo, CY;Lin, WP;Huang, SR;Wang, WY;Liao, JH;Liao, CS;Hung, YP;Lin, TH;Chang, TY;Hsiao, CF;Huang, YW;Chung, WS;Cheng, CY;Cheng, SH
日期:	2020
上传时间:	2022-08-09T08:07:31Z (UTC)
出版者:	PUBLIC LIBRARY SCIENCE
ISSN:	1932-6203
摘要:	Objective In this study, we evaluated the efficacy of hydroxychloroquine (HCQ) against coronavirus disease 2019 (COVID-19) via a randomized controlled trial (RCT) and a retrospective study. Methods Subjects admitted to 11 designated public hospitals in Taiwan between April 1 and May 31, 2020, with COVID-19 diagnosis confirmed by pharyngeal real-time RT-PCR for SARS-CoV-2, were randomized at a 2:1 ratio and stratified by mild or moderate illness. HCQ (400 mg twice for 1 d or HCQ 200 mg twice daily for 6 days) was administered. Both the study and control group received standard of care (SOC). Pharyngeal swabs and sputum were collected every other day. The proportion and time to negative viral PCR were assessed on day 14. In the retrospective study, medical records were reviewed for patients admitted before March 31, 2020. Results There were 33 and 37 cases in the RCT and retrospective study, respectively. In the RCT, the median times to negative rRT-PCR from randomization to hospital day 14 were 5 days (95% CI; 1, 9 days) and 10 days (95% CI; 2, 12 days) for the HCQ and SOC groups, respectively (p = 0.40). On day 14, 81.0% (17/21) and 75.0% (9/12) of the subjects in the HCQ and SOC groups, respectively, had undetected virus (p = 0.36). In the retrospective study, 12 (42.9%) in the HCQ group and 5 (55.6%) in the control group had negative rRT-PCR results on hospital day 14 (p = 0.70). Conclusions Neither study demonstrated that HCQ shortened viral shedding in mild to moderate COVID-19 subjects.
URI:	http://dx.doi.org/10.1371/journal.pone.0242763 https://www.webofscience.com/wos/woscc/full-record/WOS:000596569200079 https://ir.csmu.edu.tw:8080/handle/310902500/24758
關聯:	PLOS ONE ,2020 ,v15 ,issue 12
显示于类别:	[中山醫學大學研究成果] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	151	检视/开启

在CSMUIR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....